Cited 0 times in
Actual compliance to adjuvant chemotherapy in gastric cancer
|dc.description.abstract||PURPOSE: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer.
METHODS: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea.
RESULTS: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (>/=60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354): by body mass index (BMI) (>/=23 kg/m(2) vs. <23 kg/m(2)) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively.
CONCLUSION: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m(2), and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.
|dc.title||Actual compliance to adjuvant chemotherapy in gastric cancer||-|
|dc.subject.keyword||Advanced gastric cancer||-|
|dc.citation.title||Annals of surgical treatment and research||-|
|dc.identifier.bibliographicCitation||Annals of surgical treatment and research, 96(4). : 185-190, 2019||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.